



## **Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates**

April 22, 2022

*Call scheduled for Monday, April 25, 2022 8:00 a.m. ET*

*Clinical trial investigators to participate*

SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, April 25, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 1 clinical trials assessing two lead clinical programs, NKX101 and NKX019. Leading investigators from the two clinical trials will join management for the discussion.

### **Conference Call and Webcast**

To access the conference call, please dial:

+1 (866) 518-6930 (domestic)  
+1 (203) 518-9797 (international)  
Conference ID "Nkarta"

A simultaneous webcast of the conference call and accompanying slides will be available on the Investors section of Nkarta's website, [www.nkartatx.com](http://www.nkartatx.com), and a replay will be archived on the website for approximately four weeks.

### **About NKX101**

NKX101, a wholly owned program of Nkarta, is a healthy donor-derived CAR-NK investigational therapy targeting NKG2D ligands on tumor cells. NKX101 is being investigated in an ongoing Phase 1 single-arm, multi-center, open label clinical trial that is designed to assess the safety and anti-tumor activity of NKX101 as a multi-dose, multi-cycle monotherapy in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes (MDS).

### **About NKX019**

NKX019, a wholly owned program of Nkarta, is a healthy donor-derived CAR-NK investigational therapy targeting CD19. NKX019 is being investigated in an ongoing Phase 1 single-arm, multi-center, open label clinical trial that is designed to assess the safety and anti-tumor activity of NKX019 as a multi-dose, multi-cycle monotherapy in patients with relapsed/refractory B cell malignancies.

### **About Nkarta**

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at [www.nkartatx.com](http://www.nkartatx.com).

### **Nkarta Media/Investor Contact:**

Greg Mann  
Nkarta, Inc.  
[gmann@nkartatx.com](mailto:gmann@nkartatx.com)